… cell composition. The primary endpoint is the combined effect of metformin and durvalumab
on the immune TME, specifically with respect to alterations in T cell and macrophage …

… This trial was designed to explore the potential multi-mechanistic … durvalumab (Durva) and
metformin (Met) and examine alterations of key immune elements, CD8+ and FoxP3+ T cells, …

861MO Spatial distribution of CD8+ and FoxP3+ in a window of opportunity for durvalumab (MEDI4736)
plus metformin trial in squamous cell carcinoma of the head and neck (HNSCC) …

… and neck cancer patients, window of opportunity trials offers a … Window of opportunity trials
enroll patients prior to surgery … Neck Squamous Cell Carcinoma Metformin + Durvalumab …

… Major pathologic response (no more than 10% of viable tumor cells) was achieved in 3 patients
… The trial is ongoing and the updated outcomes with immune correlates will be presented …

… of the phase 2 CONDOR study (154), durvalumab, alone or in combination with … study
involving patients with HNSCC whose disease failed platinum-based chemotherapy. Durvalumab …

… are ongoing to explore the efficacy of metformin as an adjunct to ICIs. … Durvalumab Metformin
combination in Head and Neck squamous cell carcinoma proved safe in part 1 of the study …

… a study demonstrated that mTOR varied widely between tumor cores … In addition, both
Durvalumab and Atezolizumab block … Indeed, metformin inhibits the proliferation of carcinoma …

… of recurrent/metastatic squamous cell carcinoma of the head … Recently, several small
window-of-opportunity trials reported … to durvalumab plus metformin (Arm A; n = 29) or durvalumab …

… Patients in the durvalumab + metformin arm received a four-week supply of metformin to …
All subjects received 1500 mg durvalumab (MEDI4736) via IV infusion on day 3 (±2). Definitive …